Motley Fool Asset Management LLC Has $283,000 Holdings in Insulet Co. (NASDAQ:PODD)

Motley Fool Asset Management LLC cut its stake in shares of Insulet Co. (NASDAQ:PODD) by 7.5% during the 4th quarter, Holdings Channel reports. The fund owned 1,304 shares of the medical instruments supplier’s stock after selling 105 shares during the period. Motley Fool Asset Management LLC’s holdings in Insulet were worth $283,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of PODD. Syon Capital LLC acquired a new position in shares of Insulet during the fourth quarter worth approximately $288,000. Atria Wealth Solutions Inc. acquired a new position in Insulet during the fourth quarter worth $288,000. GAMMA Investing LLC bought a new position in shares of Insulet in the fourth quarter valued at $55,000. Linden Thomas Advisory Services LLC lifted its stake in shares of Insulet by 1.3% in the fourth quarter. Linden Thomas Advisory Services LLC now owns 5,817 shares of the medical instruments supplier’s stock valued at $1,262,000 after buying an additional 73 shares in the last quarter. Finally, Jennison Associates LLC grew its holdings in shares of Insulet by 57.7% during the fourth quarter. Jennison Associates LLC now owns 207,519 shares of the medical instruments supplier’s stock valued at $45,027,000 after buying an additional 75,954 shares during the last quarter.

Insulet Trading Up 1.2 %

Shares of Insulet stock opened at $166.19 on Friday. The stock has a market capitalization of $11.64 billion, a P/E ratio of 57.11, a P/E/G ratio of 2.96 and a beta of 0.98. Insulet Co. has a 52-week low of $125.82 and a 52-week high of $335.91. The company has a debt-to-equity ratio of 1.86, a quick ratio of 2.62 and a current ratio of 3.51. The stock’s 50-day simple moving average is $171.51 and its 200 day simple moving average is $179.39.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 EPS for the quarter, beating analysts’ consensus estimates of $0.67 by $0.73. Insulet had a net margin of 12.16% and a return on equity of 32.19%. The company had revenue of $509.80 million for the quarter, compared to analysts’ expectations of $461.26 million. During the same period in the prior year, the company posted $0.55 EPS. Insulet’s revenue was up 37.9% compared to the same quarter last year. As a group, research analysts anticipate that Insulet Co. will post 3.08 EPS for the current year.

Insiders Place Their Bets

In related news, Director Shacey Petrovic sold 11,609 shares of the business’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total transaction of $1,891,338.28. Following the sale, the director now directly owns 2,567 shares in the company, valued at approximately $418,215.64. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.90% of the company’s stock.

Analyst Ratings Changes

A number of research firms have issued reports on PODD. JPMorgan Chase & Co. lifted their price target on Insulet from $190.00 to $225.00 and gave the company an “overweight” rating in a research note on Friday, February 23rd. Barclays lowered their price target on Insulet from $214.00 to $213.00 and set an “equal weight” rating for the company in a research report on Monday, February 26th. Stifel Nicolaus upped their target price on shares of Insulet from $163.00 to $208.00 and gave the stock a “hold” rating in a research note on Monday, February 5th. Finally, Piper Sandler dropped their price target on shares of Insulet from $250.00 to $230.00 and set an “overweight” rating on the stock in a research report on Friday, February 23rd. Four research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $243.21.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.